Mortality and clinical response of patients with bullous pemphigoid treated with rituximab

Br J Dermatol. 2021 Jul;185(1):210-212. doi: 10.1111/bjd.19890. Epub 2021 Mar 31.

Authors

D S Yoo¹, J H Lee¹, S-C Kim², J H Kim¹

Affiliations

¹ Department of Dermatology, Gangnam Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.
² Department of Dermatology, Yongin Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Yongin, Korea.

PMID: 33657641
DOI: 10.1111/bjd.19890

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Murine-Derived
Humans
Immunologic Factors
Pemphigoid, Bullous* / drug therapy
Rituximab

Substances

Antibodies, Monoclonal, Murine-Derived
Immunologic Factors
Rituximab

Grants and funding

NRF-2018R1D1A1B07045532/National Research Foundation of South Korea